Glycogen synthase kinase 3β inhibition sensitizes human glioblastoma cells to temozolomide by affecting O6-methylguanine DNA methyltransferase promoter methylation via c-Myc signaling

Carcinogenesis

Volumn 34, Issue 10, 2013, Pages 2206-2217

  Pyko, Ilya V ^a,b   Nakada, Mitsutoshi ^a   Sabit, Hemragul ^a   Teng, Lei ^a,c   Furuyama, Natsuki ^a   Hayashi, Yutaka ^a   Kawakami, Kazuyuki ^a   Minamoto, Toshinari ^a   Fedulau, Aliaksandr S ^b   Hamada, Jun ichiro ^a  

^a KANAZAWA UNIVERSITY   (Japan)

^b BELARUSIAN STATE MEDICAL UNIVERSITY   (Belarus)

^c HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

1 (4 METHOXYBENZYL) 3 (5 NITRO 2 THIAZOLYL)UREA; GLYCOGEN SYNTHASE KINASE 3BETA; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; MYC PROTEIN; SMALL INTERFERING RNA; TEMOZOLOMIDE;

ARTICLE; CELL PROLIFERATION; ENZYME INHIBITION; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; DACARBAZINE; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DNA METHYLATION; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; GLYCOGEN SYNTHASE KINASE 3; HUMANS; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; PHOSPHORYLATION; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-MYC; SIGNAL TRANSDUCTION;

EID: 84885139912     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgt182     Document Type: Article

References (41)

1. DeAngelis, L.M. (2001) Brain tumors. N. Engl. J. Med., 344, 114-123.
2. Lefranc, F. et al. (2005) Possible future issues in the treatment of glioblastomas: special emphasis on cell migration and the resistance of migrating glioblastoma cells to apoptosis. J. Clin. Oncol., 23, 2411-2422.
3. Stewart, L.A. (2002) Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet, 359, 1011-1018.
4. Miyashita, K. et al. (2009) An emerging strategy for cancer treatment targeting aberrant glycogen synthase kinase 3 beta. Anticancer. Agents Med. Chem., 9, 1114-1122.
5. Nakada, M. et al. (2011) The pivotal role of GSK3β in glioma biology. In Garami, M. (ed.) Molecular Targets of CNS Tumors. InTech, Croatia, pp. 567-590.
6. Hegi, M.E. et al. (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med., 352, 997-1003.
7. Costello, J.F. et al. (1994) Graded methylation in the promoter and body of the O6-methylguanine DNA methyltransferase (MGMT) gene correlates with MGMT expression in human glioma cells. J. Biol. Chem., 269, 17228-17237.
8. Jope, R.S. et al. (2004) The glamour and gloom of glycogen synthase kinase-3. Trends Biochem. Sci., 29, 95-102.
9. Bhat, R. et al. (2003) Structural insights and biological effects of glycogen synthase kinase 3-specific inhibitor AR-A014418. J. Biol. Chem., 278, 45937-45945.
10. Miyashita, K. et al. (2009) Potential therapeutic effect of glycogen synthase kinase 3 beta inhibition against human glioblastoma. Clin. Cancer Res., 15, 887-897.
11. Gregory, M.A. et al. (2003) Phosphorylation by glycogen synthase kinase-3 controls c-myc proteolysis and subnuclear localization. J. Biol. Chem., 278, 51606-51612.
12. Kotliarova, S. et al. (2008) Glycogen synthase kinase-3 inhibition induces glioma cell death through c-MYC, nuclear factor-kappaB, and glucose regulation. Cancer Res., 68, 6643-6651.
13. Louis, D.N. et al. (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol., 114, 97-109.
14. Yoshida, Y. et al. (2010) Sphingosine-1-phosphate receptor type 1 regulates glioma cell proliferation and correlates with patient survival. Int. J. Cancer, 126, 2341-2352.
15. Wauthoz, N. et al. (2010) In vivo assessment of temozolomide local delivery for lung cancer inhalation therapy. Eur. J. Pharm. Sci., 39, 402-411.
16. Nakada, M. et al. (2005) EphB2/R-Ras signaling regulates glioma cell adhesion, growth, and invasion. Am. J. Pathol., 167, 565-576.
17. Breinholt, V. et al. (1998) Detection of weak estrogenic flavonoids using a recombinant yeast strain and a modified MCF7 cell proliferation assay. Chem. Res. Toxicol., 11, 622-629.
18. Steel, G.G. et al. (1979) Exploitable mechanisms in combined radiotherapy- chemotherapy: the concept of additivity. Int. J. Radiat. Oncol. Biol. Phys., 5, 85-91.
19. Chou, T.C. et al. (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul., 22, 27-55.
20. Chou, T.C. (2006) Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol. Rev., 58, 621-681.
21. Palmisano, W.A. et al. (2000) Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res., 60, 5954-5958.
22. Suzuki, T. et al. (2011) The correlation between promoter methylation status and the expression level of O6-methylguanine-DNA methyltransferase in recurrent glioma. Jpn. J. Clin. Oncol., 41, 190-196.
23. Eads, C.A. et al. (2001) Epigenetic patterns in the progression of esophageal adenocarcinoma. Cancer Res., 61, 3410-3418.
24. Weisenberger, D.J. et al. (2005) Analysis of repetitive element DNA methylation by MethyLight. Nucleic Acids Res., 33, 6823-6836.
25. Mariani, L. et al. (2001) Identification and validation of P311 as a glioblastoma invasion gene using laser capture microdissection. Cancer Res., 61, 4190-4196.
26. Rolhion, C. et al. (1999) O(6)-methylguanine-DNA methyltransferase gene (MGMT) expression in human glioblastomas in relation to patient characteristics and p53 accumulation. Int. J. Cancer, 84, 416-420.
27. Nowak, D.E. et al. (2005) Two-step cross-linking method for identification of NF-kappaB gene network by chromatin immunoprecipitation. Biotechniques, 39, 715-725.
28. Bilim, V. et al. (2009) Glycogen synthase kinase-3: a new therapeutic target in renal cell carcinoma. Br. J. Cancer, 101, 2005-2014.
29. Baek, S.H. et al. (2003) Regulated subset of G1 growth-control genes in response to derepression by the Wnt pathway. Proc. Natl Acad. Sci. USA, 100, 3245-3250.
30. Brenner, C. et al. (2005) Myc represses transcription through recruitment of DNA methyltransferase corepressor. EMBO J., 24, 336-346.
31. Kanzawa, T. et al. (2003) Inhibition of DNA repair for sensitizing resistant glioma cells to temozolomide. J. Neurosurg., 99, 1047-1052.
32. Torres, S. et al. (2011) A combined preclinical therapy of cannabinoids and temozolomide against glioma. Mol. Cancer Ther., 10, 90-103.
33. Ostermann, S. et al. (2004) Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients. Clin. Cancer Res., 10, 3728-3736.
34. Plummer, E.R. et al. (2005) Temozolomide pharmacodynamics in patients with metastatic melanoma: DNA damage and activity of repair enzymes O6-alkylguanine alkyltransferase and poly(ADP-ribose) polymerase-1. Clin. Cancer Res., 11, 3402-3409.
35. Steiner, P. et al. (1995) Identification of a Myc-dependent step during the formation of active G1 cyclin-cdk complexes. EMBO J., 14, 4814-4826.
36. Packham, G. et al. (1995) c-Myc and apoptosis. Biochim. Biophys. Acta, 1242, 11-28.
37. Askew, D.S. et al. (1991) Constitutive c-myc expression in an IL-3-dependent myeloid cell line suppresses cell cycle arrest and accelerates apoptosis. Oncogene, 6, 1915-1922.
38. Pulverer, B.J. et al. (1994) Site-specific modulation of c-Myc cotransformation by residues phosphorylated in vivo. Oncogene, 9, 59-70.
39. Hirose, Y. et al. (2001) Abrogation of the Chk1-mediated G(2) checkpoint pathway potentiates temozolomide-induced toxicity in a p53-independent manner in human glioblastoma cells. Cancer Res., 61, 5843-5849.
40. Hirose, Y. et al. (2001) p53 effects both the duration of G2/M arrest and the fate of temozolomide-treated human glioblastoma cells. Cancer Res., 61, 1957-1963.
41. Zeller, K.I. et al. (2003) An integrated database of genes responsive to the Myc oncogenic transcription factor: identification of direct genomic targets. Genome Biol., 4, R69.